BioReference Laboratories Inc. in Elmwood Park acquired the U.S. Ariosa centralized laboratory prenatal testing business from Roche. The Harmony Prenatal Test, Ariosa’s non-invasive prenatal screening ...
BioReference Health, formerly known as BioReference Laboratories, and OPKO Health have agreed to pay $9.85 million to resolve alleged violations of the False Claims Act arising from BioReference’s ...
Ariosa's non invasive prenatal screening (NIPS) test, the Harmony Prenatal Test, is one of the most widely studied tests utilized in prenatal screening. The test has been performed in over 1.5 million ...
Elmwood Par, NJ, Aug. 01, 2019 (GLOBE NEWSWIRE) -- BioReference Laboratories, Inc., one of the largest clinical laboratories in the United States, today announced it has been selected by The IPA ...
ELMWOOD PARK, N.J.--(BUSINESS WIRE)--BioReference Laboratories, Inc. (NASDAQ: BRLI) announced today that it has received a letter from Horizon Blue Cross Blue Shield of New Jersey (Horizon) ...
Scarlet brings diagnostic service to patients' homes, offices and other preferred locations, delivering an on-demand, safe and convenient diagnostic experience for patients and healthcare providers ...
ELMWOOD PARK, N.J.--(BUSINESS WIRE)-- BioReference Laboratories, Inc. (NASDAQ: BRLI) and its GenPath Oncology business unit and through its exclusive commercialization agreement with the Massachusetts ...
ELMWOOD PARK, N.J., Aug. 16, 2021 /PRNewswire/ — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the acquisition of the U.S. Ariosa centralized laboratory ...
ELMWOOD PARK, N.J.--(BUSINESS WIRE)-- BioReference Laboratories, Inc. (NASDAQ: BRLI) and its GenPath Oncology business unit and through its exclusive commercialization agreement with the Massachusetts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback